(Yahoo! Finance) Feb 7, 2019 - Karyopharm Therapeutics Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the Company’s New Drug Application (NDA) requesting accelerated approval for selinexor, a first-in-class, oral Selective...
(PMLiVE [UK]) Feb 5, 2019 - Sanofi’s bid to grab a slice of the multiple myeloma market has advanced thanks to a positive phase 3 trial of isatuximab in relapsed/refractory patients with the blood cancer.
Top-line results from the ICARIA-MM trial reveal that the CD38-targeting antibody was able to prolong progression-free survival...
There are no Multiple Myeloma OBR Green articles.